Verdiva Bio
Mohammed Khaled Junaidi, MD, currently serves as the Vice President of Clinical Research at Verdiva Bio since January 2025, and previously held the same title at Sciwind Biosciences from June 2022 to December 2024. With extensive experience in clinical research and medical leadership, positions included Senior Medical Director and Medical Director at Xeris Pharmaceuticals, Inc. from October 2017 to June 2022, and Associate Director of Clinical Development at Affinity Health, focusing on endocrinology. Mohammed has also contributed as Medical Team Lead at CallHealth and as a consultant in private practice specializing in internal medicine and diabetes. Educational background includes an MD in Internal Medicine from Kempegowda Institute of Medical Sciences and an MBBS from Al-Ameen Medical College.
This person is not in the org chart
This person is not in any offices
Verdiva Bio
1 followers
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit www.verdivabio.com.